These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15006404)

  • 1. Thrombin inhibitors built on an azaphenylalanine scaffold.
    Zega A; Mlinsek G; Solmajer T; Trampus-Bakija A; Stegnar M; Urleb U
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1563-7. PubMed ID: 15006404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and in vitro evaluation of new azaphenylalanine derivatives as serine protease inhibitors.
    Obreza A; Stegnar M; Trampus-Bakija A; Prezelj A; Urleb U
    Pharmazie; 2004 Oct; 59(10):739-43. PubMed ID: 15544050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel non-covalent azaphenylalanine thrombin inhibitors with an aminomethyl or amino group at the P1 position.
    Obreza A; Stegnar M; Urleb U
    Pharmazie; 2004 Sep; 59(9):659-67. PubMed ID: 15497744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of weakly basic thrombin inhibitors incorporating novel P1 binding functions: molecular and X-ray crystallographic studies.
    De Simone G; Menchise V; Omaggio S; Pedone C; Scozzafava A; Supuran CT
    Biochemistry; 2003 Aug; 42(30):9013-21. PubMed ID: 12885234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel thrombin inhibitors with azaphenylalanine scaffold.
    Zega A; Trampus-Bakija A; Fortuna M; Stegnar M; Tschopp TB; Steiner B; Urleb U
    Pharmazie; 2001 Sep; 56(9):683-5. PubMed ID: 11593985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel azapeptide inhibitors of hepatitis C virus serine protease.
    Bailey MD; Halmos T; Goudreau N; Lescop E; Llinàs-Brunet M
    J Med Chem; 2004 Jul; 47(15):3788-99. PubMed ID: 15239657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compounds binding to the S2-S3 pockets of thrombin.
    Nilsson M; Hämäläinen M; Ivarsson M; Gottfries J; Xue Y; Hansson S; Isaksson R; Fex T
    J Med Chem; 2009 May; 52(9):2708-15. PubMed ID: 19371038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The methyl group of N(alpha)(Me)Arg-containing peptides disturbs the active-site geometry of thrombin, impairing efficient cleavage.
    Friedrich R; Steinmetzer T; Huber R; Stürzebecher J; Bode W
    J Mol Biol; 2002 Mar; 316(4):869-74. PubMed ID: 11884127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prodrug-based design, synthesis, and biological evaluation of N-benzenesulfonylpiperidine derivatives as novel, orally active factor Xa inhibitors.
    Ishihara T; Seki N; Hirayama F; Orita M; Koshio H; Taniuchi Y; Sakai-Moritani Y; Iwatsuki Y; Kaku S; Kawasaki T; Matsumoto Y; Tsukamoto S
    Bioorg Med Chem; 2007 Jun; 15(12):4175-92. PubMed ID: 17416533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bound structures of novel P3-P1' beta-strand mimetic inhibitors of thrombin.
    St Charles R; Matthews JH; Zhang E; Tulinsky A
    J Med Chem; 1999 Apr; 42(8):1376-83. PubMed ID: 10212123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From natural products to achiral drug prototypes: potent thrombin inhibitors based on P2/P3 dihydropyrid-2-one core motifs.
    Hanessian S; Therrien E; Zhang J; Otterlo Wv; Xue Y; Gustafsson D; Nilsson I; Fjellström O
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5429-32. PubMed ID: 19674897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesis.
    Lu T; Markotan T; Coppo F; Tomczuk B; Crysler C; Eisennagel S; Spurlino J; Gremminger L; Soll RM; Giardino EC; Bone R
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3727-31. PubMed ID: 15203151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation of L-proline based aeruginosin 298-A analogs: optimization of the P1-moiety.
    Wang G; Goyal N; Hopkinson B
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3798-803. PubMed ID: 19447619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal structures of thrombin complexed to a novel series of synthetic inhibitors containing a 5,5-trans-lactone template.
    Jhoti H; Cleasby A; Reid S; Thomas PJ; Weir M; Wonacott A
    Biochemistry; 1999 Jun; 38(25):7969-77. PubMed ID: 10387040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporation of neutral C-terminal residues in 3-amidinophenylalanine-derived matriptase inhibitors.
    Schweinitz A; Dönnecke D; Ludwig A; Steinmetzer P; Schulze A; Kotthaus J; Wein S; Clement B; Steinmetzer T
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1960-5. PubMed ID: 19250826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative binding energy analysis considering multiple receptors: a step toward 3D-QSAR models for multiple targets.
    Murcia M; Morreale A; Ortiz AR
    J Med Chem; 2006 Oct; 49(21):6241-53. PubMed ID: 17034130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel thrombin inhibitors incorporating weakly basic heterobicyclic P1-arginine mimetics: optimization via modification of P1 and P3 moieties.
    Kranjc A; Peterlin-Masic L; Ilas J; Prezelj A; Stegnar M; Kikelj D
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3251-6. PubMed ID: 15149685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of ligand conformations in continuum solvent consistent with protein active site topology: application to thrombin.
    Greenidge PA; Mérette SA; Beck R; Dodson G; Goodwin CA; Scully MF; Spencer J; Weiser J; Deadman JJ
    J Med Chem; 2003 Apr; 46(8):1293-305. PubMed ID: 12672230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of hydrophobic interactions and hydrogen bond strength by cooperativity: synthesis, modeling, and molecular dynamics simulations of a congeneric series of thrombin inhibitors.
    Muley L; Baum B; Smolinski M; Freindorf M; Heine A; Klebe G; Hangauer DG
    J Med Chem; 2010 Mar; 53(5):2126-35. PubMed ID: 20148533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of novel thrombin inhibitors. Use of ring-closing metathesis reactions for synthesis of P2 cyclopentene- and cyclohexenedicarboxylic acid derivatives.
    Thorstensson F; Kvarnström I; Musil D; Nilsson I; Samuelsson B
    J Med Chem; 2003 Mar; 46(7):1165-79. PubMed ID: 12646027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.